BioWorld

Jan. 30, 2002

DeCode, Roche Sign New Deal For Compound Development

DeCode Genetics Inc. and Roche Holdings SA signed a three-year alliance to discover and develop therapeutics based on the achievements of a previous gene discovery collaboration between the companies. (BioWorld Today) Read More

Cancer Efforts Continuing As OSI Plans To Sell $200M In Notes

Gene For Auditory Hallucination In Hyper-Rare Epilepsy Variant Sheds Light On Common Illness

DOV Pharmaceuticals Enters IPO Ring, Bids For $86.2M

Other News To Note

Triangle CEO, Antivirals Pioneer Barry Passes Away

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...